NantHealth
Market Cap
US$82.1m
Last Updated
2019/10/18 00:43 UTC
Data Sources
Company Financials +
Executive Summary
NantHealth, Inc., together with its subsidiaries, operates as a healthcare technology company in the United States and internationally.
Snowflake
Fundamentals
Slightly overvalued with concerning outlook.
Similar Companies
Share Price & News
How has NantHealth's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
0.3%
NH
1.4%
US Healthcare Services
1.8%
US Market
1 Year Return
-45.8%
NH
15.6%
US Healthcare Services
7.3%
US Market
Return vs Industry: NH underperformed the US Healthcare Services industry which returned 15.6% over the past year.
Return vs Market: NH underperformed the US Market which returned 7.3% over the past year.
Shareholder returns
| NH | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.3% | 1.4% | 1.8% |
| 30 Day | -9.9% | -0.9% | -0.7% |
| 90 Day | 33.1% | -5.3% | 0.06% |
| 1 Year | -45.8%-45.8% | 15.8%15.6% | 9.7%7.3% |
| 3 Year | -94.5%-94.5% | 57.1%56.6% | 46.3%36.9% |
| 5 Year | n/a | 49.8%48.7% | 64.5%46.5% |
Price Volatility Vs. Market
How volatile is NantHealth's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
Did You Manage To Avoid NantHealth's (NASDAQ:NH) Devastating 94% Share Price Drop?1 month ago | Simply Wall St
Health Check: How Prudently Does NantHealth (NASDAQ:NH) Use Debt?2 months ago | Simply Wall St
Before You Buy NantHealth, Inc. (NASDAQ:NH), Consider Its VolatilityValuation
Is NantHealth undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Undervalued: NH ($0.74) is trading below our estimate of fair value ($9.91)
Significantly Undervalued: NH is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NH is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.
PE vs Market: NH is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate NH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NH has negative assets, so we can't compare its PB Ratio to the US Healthcare Services industry average.
Next Steps
Future Growth
How is NantHealth forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
43.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NH's revenue (11.7% per year) is forecast to grow faster than the US market (7.3% per year).
High Growth Revenue: NH's revenue (11.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: NH is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has NantHealth performed over the past 5 years?
-17.2%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: NH is unprofitable, and losses have increased over the past 5 years at a rate of -17.2% per year.
Accelerating Growth: Unable to compare NH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NH is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (3.3%).
Return on Equity
High ROE: NH's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
ROA vs Industry: NH is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: NH is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is NantHealth's financial position?
Financial Position Analysis
Short Term Liabilities: NH has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: NH has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: NH has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: NH's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Inventory Level: NH has a low level of unsold assets or inventory.
Debt Coverage by Assets: NH has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NH has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if NH has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is NantHealth's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate NH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate NH's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if NH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NH's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of NantHealth's salary, the management and board of directors tenure and is there insider trading?
2.0yrs
Average management tenure
CEO
Patrick Soon-Shiong (66yo)
9.3yrs
Tenure
Dr. Patrick Soon-Shiong, M.D., FRCS (C), FACS, MBBCh, MSc, FRCS (C), is an Owner of Los Angeles Times Communications, LLC. Dr. Soon-Shiong is a physician, surgeon and scientist, invented and developed the ...
Management Age and Tenure
2.0yrs
Average Tenure
54yo
Average Age
Experienced Management: NH's management team is considered experienced (2 years average tenure).
Board Age and Tenure
3.4yrs
Average Tenure
67yo
Average Age
Experienced Board: NH's board of directors are considered experienced (3.4 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Management Team
Patrick Soon-Shiong (66yo)
Founder
- Tenure: 9.3yrs
Ron Louks (54yo)
COO & Director
- Tenure: 1.3yrs
- Compensation: US$718.53k
Bobby Reddy
Chief Medical Officer
- Tenure: 2.4yrs
Brandon Villery
VP, General Counsel & Corporate Secretary
- Tenure: 2yrs
Keith Krebs
Senior Vice President of Client Services
- Tenure: 2yrs
Chris House
Senior Vice President of Product Development
- Tenure: 2yrs
Maureen Becker
Vice President of Human Resources
- Tenure: 1.7yrs
Bob Petrou (47yo)
Chief Financial Officer
- Tenure: 1.1yrs
- Compensation: US$490.43k
Mark Mozley
Senior VP of Global Sales & Marketing
- Tenure: 1.8yrs
Board Members
Patrick Soon-Shiong (66yo)
Founder
- Tenure: 9.3yrs
Michael Blaszyk (67yo)
Director
- Tenure: 3.4yrs
- Compensation: US$248.80k
Kirk Calhoun (75yo)
Director
- Tenure: 3.4yrs
- Compensation: US$240.05k
Michael Sitrick (72yo)
Director
- Tenure: 3.4yrs
- Compensation: US$246.30k
Ron Louks (54yo)
COO & Director
- Tenure: 1.3yrs
- Compensation: US$718.53k
Company Information
NantHealth, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: NantHealth, Inc.
- Ticker: NH
- Exchange: NasdaqGS
- Founded: 2010
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: US$82.075m
- Shares outstanding: 110.63m
- Website: https://nanthealth.com
Number of Employees
Location
- NantHealth, Inc.
- 9920 Jefferson Boulevard
- Culver City
- California
- 90232
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| NH | NasdaqGS (Nasdaq Global Select) | Yes | Common Shares | US | USD | Jun 2016 |
| NEL | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Jun 2016 |
Biography
NantHealth, Inc., together with its subsidiaries, operates as a healthcare technology company in the United States and internationally. The company engages in converging science and technology through an i ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/18 00:43 |
| End of Day Share Price | 2019/10/17 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.